The story: An April 2026 Telegraph investigation describes an influencer-fuelled grey market in which men and women buy and self-inject unregulated peptides — Melanotan II, retatrutide, BPC-157, TB-500, GHK-Cu — often described in code and stamped “for research purposes only”. Experts quoted warn the product is frequently not clean, that human safety data is limited or absent, and that regulators such as the MHRA are stepping up enforcement. The takeaway for the research-compound world is blunt: “research use only” is a legal line that means not for human consumption — not a marketing wink, and not a green light to inject.
This article summarises and comments on reporting by The Telegraph: Nick Harding, “Unregulated drugs are turning vain men and women into human guinea pigs” (3 April 2026). Read the original for the full report. New-U is independent and not affiliated with The Telegraph; the link carries no endorsement either way.
Every so often a news feature holds up a mirror to a corner of the internet, and the reflection is unflattering. The Telegraph’s April 2026 long read does exactly that for the peptide “grey market” — the influencer-driven subculture where compounds meant for the laboratory bench are repackaged as chemical shortcuts to a tan, a six-pack or “superhuman healing”, and then injected by people at home. It is worth reading in full, and it is worth taking seriously. Below is a summary of what it found, and where a responsible, research-use-only supplier sits in relation to it.
The piece follows fitness influencers who document their own peptide use to large social-media audiences, talking “in code about compounds, usually with the disclaimer ‘for research purposes only’”. It maps a now-familiar menu of grey-market compounds: Melanotan II (the “tan jab” or “Barbie drug”), retatrutide (a GLP-1-class drug still in clinical trials, nicknamed “Red Tide” and “Triple G”), BPC-157 and TB-500 (often combined into a “Wolverine stack” sold on a promise of near-superhuman recovery), and GHK-Cu (“Smurf Juice”, marketed for skin and hair). The thread running through all of it: in their injectable, off-label forms, none is approved for general human use, and the “research use only” phrase is being parroted as cover.
This is the part the report gets exactly right, and the part most worth amplifying. The MHRA’s position, quoted in the piece, is that where products are promoted or used as medicines they fall within existing medicines law — and that the “research use only” label should be treated as a red flag, not a reassurance. That is precisely the point. Research-use-only is a classification that means a material is supplied for laboratory research and is not for human consumption. It is not a quality grade, it is not a dosing instruction, and it is certainly not permission to inject. A seller who uses “RUO” as a wink-and-nudge while coaching customers on self-injection is misusing the term, not honouring it.
Where New-U sits. New-U Research Compounds supplies lyophilised reference material to researchers, labelled research use only, not for human consumption, with no dosing or therapeutic guidance. That is a deliberately different posture from the influencer market the Telegraph describes. The compounds overlap; the framing does not. This page is general information, not legal or medical advice — do not use unapproved peptides on people.
One of the most important quotes in the feature comes from Dr Rachael Dickman of UCL, who researches peptide therapeutics: “We test them when they arrive. Often they’re not clean. The process to make something suitable to inject into a person is very different to the process to make something suitable for use in the lab.” An influencer in the same piece does the maths out loud on a cheap source — ten 100 mg vials for $55 — and concludes there is “no way they’re making any money if they’re testing their products as well”.
That is the whole game. The only way to know what is actually in a vial is to test it, independently, every batch. In the research-compound world that means a Certificate of Analysis — HPLC purity and mass-spec identity from a third-party laboratory — rather than a claim on a label. Our guides on verifying a peptide source and CoA purity and traceability set out what that verification actually looks like and how to read it.
For readers who want the descriptive, research-framed background on the molecules in the article — what each is, what study contexts it appears in, and where the human-evidence gap sits — our compound profiles cover them:
The report situates the peptide boom inside a much larger problem. It cites Europol’s Operation Shield uncovering networks producing counterfeit peptide and weight-loss drugs alongside anabolic steroids in underground labs, and an MHRA enforcement push that has seized large hauls labelled as retatrutide from sites without sterile controls or quality assurance. Eli Lilly, quoted in the piece, says it has tested counterfeit medicines and found “critical issues” capable of causing significant harm, and warns that buying prescription-only medicine from social media is “rolling the dice with your health”. The global trade in counterfeit medicines is estimated at up to $432bn a year. None of that is a footnote — it is the central risk of buying injectables from anonymous online sellers.
To its credit, the feature does not flatten the topic into “all snake oil”. It gives space to Prof Predrag Sikiric, who first isolated BPC-157 in the 1990s, and to a body of research describing accelerated healing in gastrointestinal and other tissues, plus a reassuring toxicology record in the studies he worked on. His own position is careful: he cannot endorse people buying unapproved substances online, and lack of approval is not the same as proof of danger. That nuance is exactly why the responsible framing matters. Some of these compounds are promising and incomplete; others rest on animal or early-stage data with little or no long-term human safety record. “Promising in the literature” and “tested, approved and safe to inject” are not the same sentence.
What did the Telegraph investigation say?
That an influencer-fuelled grey market is driving people to self-inject unregulated peptides; that grey-market product is often not clean; and that the “research use only” label is being used as cover. (Nick Harding, 3 April 2026.)
Does “research use only” mean safe to inject?
No. It is a legal classification meaning supplied for laboratory research, not for human consumption. It is not a quality grade and not permission to inject.
How is purity actually verified?
By independent, per-batch testing — a third-party Certificate of Analysis with HPLC purity and mass-spec identity — not by a claim on a label.
Primary source: The Telegraph, Nick Harding, “Unregulated drugs are turning vain men and women into human guinea pigs” (3 April 2026). External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalogAt New-U, we believe better conversations start with better information. For laboratory research use only. Not for human consumption.